

Technology/ Title	Novel Therapeutic Inducible Exosome (iExo) Platform for Regenerative Medicine	
Subtitle	N/A	
Technology Type	<input checked="" type="checkbox"/> Biotechnology	<input type="checkbox"/> Device/Diagnostics
Contact Person	Name: Andy Tseng	Title: Manager
	Telephone(work): +886-37246166-33211	Mobile:
	Email: anlitseng@nhri.edu.tw	
Link	https://cs.nhri.edu.tw/investigators/李華容/	
Technology Description	<p>Introduction:</p> <p>Exosomes were at best regarded as waste-disposal vessels or by-products of cell homeostasis until the seminal study demonstrated that B cells can actually release functional antigen-transferring exosomes. Recently, the scope of exosome as “nanocarriers” has gained particular interest with the discovery of a plethora of intrinsic biocargoes and their therapeutic potentials. The paradigm has shifted to the controlled bioproduction of therapeutic exosomes under qualified process.</p> <p><u>Key Features</u></p> <ul style="list-style-type: none"> • NHRI holds the design and synthesis of novel exosome inducers as such can direct the regulated sorting of relevant bioactive cargos into the collected exosomes • Platform was implemented with Deep Learning/AI capacity <p><u>Pharmaceutical Development</u></p> <ul style="list-style-type: none"> • Opportunity for large-scale bioproduction of inducible exosomes <p><u>Market Positioning</u></p> <ul style="list-style-type: none"> • The iExo harness intrinsic stemness transferring from respective mesenchymal stem cells and such MSC-derived iExo can be employed as regeneration medicine for several unmet medical needs in area of brain associated diseases. 	

Intellectual Property	US provisional <i>in prep</i>
Key Publications	Stem Cells Transl Med 2019 ; 8(7):707-723 Stem Cells Transl Med 2020 ; 9:499-517
Business Opportunity	Technology transfer; Co-development

